NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,428.50 -10.00 (-0.41%) DOW
39,867.99 +61.22 (+0.15%) Bitcoin GBP
54,475.81 +31.63 (+0.06%)
MDGL May 2024 410.000 put
| Previous close | 206.80 |
| Open | N/A |
| Bid | 185.00 |
| Ask | 194.80 |
| Strike | 410.00 |
| Expiry date | 2024-05-17 |
| Day's range | 206.80 - 206.80 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.3 High Insider Ownership US Stocks With Up To 55% Revenue Growth
Amidst a robust week for U.S. stocks, fueled by significant advancements in AI and cloud computing from major technology firms, the market landscape appears increasingly conducive to exploring growth opportunities. In this context, companies with high insider ownership can be particularly compelling, as they often signal strong confidence from those who know the business best.
GuruFocus.comJohn Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role
Insight into Paulson's Latest 13F Filings and Its Impact on His Investment Portfolio
Insider MonkeyMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript May 7, 2024 Madrigal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-7.38 EPS, expectations were $-6.06. MDGL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
